Contract preclinical study/clinical trial
Total Trials
23
As Lead Sponsor
22
As Collaborator
1
Total Enrollment
943
NCT00317811
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase 2
Role: Lead Sponsor
Start: Nov 30, 2005
Completion: Not specified
NCT00316940
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase 1
Start: Dec 31, 2005
Completion: Feb 28, 2011
NCT00742404
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Start: Jul 31, 2008
NCT00743288
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
Phase: Phase 1/2
Completion: Dec 31, 2012
NCT01160484
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
Start: Sep 30, 2009
Completion: Sep 30, 2012
NCT01160380
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Phase: Phase 3
Start: Jun 30, 2010
Completion: May 31, 2014
NCT01365559
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Start: May 2, 2011
Completion: Mar 1, 2016
NCT01541332
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Start: Feb 29, 2012
Completion: Dec 31, 2016
NCT01695330
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
Start: May 31, 2012
Completion: Oct 31, 2015
NCT01697839
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients
Phase: N/A
Start: Jun 30, 2012
Completion: Aug 31, 2015
NCT01792102
Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
Start: Apr 30, 2013
Completion: Dec 31, 2018
NCT02188368
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Start: Jul 7, 2014
Completion: Oct 23, 2020
NCT02206425
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Start: Sep 30, 2014
Completion: Mar 6, 2018
NCT02285101
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors
Role: Collaborator
Start: Nov 30, 2014
Completion: Feb 28, 2019
NCT02294357
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Start: Dec 31, 2014
Completion: Sep 22, 2020
NCT03110822
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Start: Feb 1, 2017
Completion: Feb 28, 2027
NCT03104270
Combination Study for High Risk Multiple Myeloma Patients
Start: Mar 13, 2017
Completion: Jan 23, 2020
NCT03733691
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
Start: Mar 1, 2019
Completion: Oct 19, 2023
NCT04519476
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Start: Nov 1, 2020
Completion: Dec 29, 2023
NCT06209606
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Phase: Early Phase 1
Start: Dec 8, 2022
Completion: Feb 28, 2029
NCT06115135
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Start: Jun 20, 2024
Completion: Dec 31, 2027
NCT06225310
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Start: Aug 6, 2024
Completion: May 1, 2027
Loading map...